Clinical outcomes with besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis due to potentially consequential pathogens
Timothy L Comstock,1 Timothy W Morris,2 Lynne S Gearinger,2 Heleen H DeCory11Medical Affairs, 2Department of Microbiology and Sterilization Sciences, Bausch + Lomb, Rochester, NY, USAPurpose: Besifloxacin is a chlorofluoroquinolone approved for use in the treatment of bacterial conjunctivitis. This...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2014-04-01
|
| Series: | Clinical Optometry |
| Online Access: | http://www.dovepress.com/clinical-outcomes-with-besifloxacin-ophthalmic-suspension-06-in-the-tr-a16297 |